Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Hiltz

Family Medicine Muncie, IN Medical Doctor

NPI 1568437572 CMS profile 162154

503 S Tillotson Ave, Muncie, IN 47304

Open in the dashboard

General payments

$177,271

559 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Hiltz of Muncie, IN is reported in the CMS Open Payments database as having received $177,271 across 559 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,055 19
2024 General $27,999 16
2023 General $18,913 13
2022 General $26,577 91
2021 General $26,469 183
2020 General $25,597 121
2019 General $24,660 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Hiltz
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Jeffrey Hiltz were reported at $27,055. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Jeffrey Hiltz Family Medicine median Middle half National median
2019 $24,660 $150 $41–$543 $163
2020 $25,597 $120 $32–$415 $114
2021 $26,469 $137 $35–$551 $132
2022 $26,577 $137 $37–$512 $149
2023 $18,913 $149 $42–$545 $160
2024 $27,999 $156 $44–$560 $164
2025 $27,055 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $147,659 97 payments
  2. Shire North American Group Inc $23,100 12 payments
  3. AstraZeneca Pharmaceuticals LP $1,046 40 payments
  4. Lilly USA, LLC $872 79 payments
  5. AbbVie, Inc. $580 64 payments
  6. Astellas Pharma US Inc $559 17 payments
  7. Novo Nordisk Inc $383 33 payments
  8. GlaxoSmithKline, LLC. $336 44 payments
  9. Sun Pharmaceutical Industries Inc. $329 5 payments
  10. Janssen Pharmaceuticals, Inc $256 16 payments
  11. Other $2,151 152 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $170,006 86 payments
  2. Food and Beverage $6,262 464 payments
  3. Travel and Lodging $611 4 payments
  4. Education $392 5 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $807 32 payments
  2. TRULICITY $346 27 payments
  3. VRAYLAR $291 29 payments
  4. JARDIANCE $289 27 payments
  5. XARELTO $256 16 payments
  6. TRELEGY ELLIPTA $253 36 payments
  7. EMGALITY $233 37 payments
  8. Ozempic $196 16 payments
  9. MYRBETRIQ $181 13 payments
  10. LOKELMA $175 3 payments
  11. Other $4,115 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 261 drugs

Part D claims

22,113

Median for Family Practice: 1,826

Drug cost

$1,561,196

Median for Family Practice: $120,094

Branded share of claims

27.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,029 $329,590
Xifaxan Rifaximin Brand 52 $93,506
Nuplazid Pimavanserin Tartrate Brand 21 $49,877
Jardiance Empagliflozin Brand 143 $45,346
Xarelto Rivaroxaban Brand 149 $43,333
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 74 $42,863
Invega Sustenna Paliperidone Palmitate Brand 17 $40,372
Ozempic Semaglutide Brand 28 $29,461
Myrbetriq Mirabegron Brand 100 $29,094
Autoshield Duo Pen Needle Pen Needle,dual Safety,diabetc Brand 238 $24,595

The 10 drugs with the highest cost, of 261 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$183,938

Medicare's payments for the services billed

Medicare patients

457

Average age 80

Services billed

2,196

304 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Depression 56%
Alzheimer's or dementia 50%
Chronic kidney disease 48%
Diabetes 47%
Heart failure 46%
Ischemic heart disease 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record